IBC Services

Sitero manages Institutional Biosafety Committees (IBC) for institutions externally that meet all NIH guidelines and requirements.

An Institutional Biosafety Committee (IBC) is an institution specific regulatory committee responsible for the review of research projects that use recombinant or synthetic nucleic acid molecules (r/sNA). An IBC ensures that research complies with the National Institute of Health (NIH) guidelines.

This review is required by NIH for any facility or project funded by state or local governments and is based at the location doing the research or administering the product.

The main responsibility of an IBC is to independently assess the biosafety of the recombinant material in research. IBC review is considered best-practice even if the project is privately funded.

IBC services are used when an organization does not have the resources or expertise to establish an internal IBC or when an independent review is desired for added assurance and transparency. An external IBC comprehensively evaluates the biosafety and biosecurity risks associated with using biological agents in research, production, and other activities.

They also review and approve proposals for the use of hazardous biological materials and provide guidance on compliance with regulatory requirements and best practices. External IBC services can provide an objective and expert evaluation of an organization’s biosafety program, ensuring that all aspects of the program comply with local, national, and international regulations and promoting the safe and responsible use of biological agents.

Sitero’s IBC experts will collaborate closely with your staff to guarantee the precise completion and prompt submission of all necessary forms to NIH. By taking advantage of this no-cost IBC registration with NIH, you can save significant time and resources, as it can help speed up the approval process and cut 4-6 weeks off your site activation for a gene therapy trial.

Sitero offers a distinctive Site Network Central IBC model for site networks with multiple locations that simplify IBC requirements across sites. This model ensures that all sites within a network comply with the same set of IBC requirements, reducing confusion and errors and improving overall trial outcomes.

If you are interested in discovering more about Sitero’s IBC solutions or wish to avail yourself of this offer for a free NIH registration, please contact us:

When ASLA Research needed help understanding what was required for their site network’s Institutional Biosafety Committee (IBC), Sitero guided them every step of the way. Hear directly from ASLA’s CEO, Jeff Stein, and Sitero’s VP of IRB, IBC & Biosafety, Sarah A. Ziegler, in this client testimony. 

Sitero IBC has the Biosafety experts to help review and ensure the safety of infectious biological material. We ensure compliance with the NIH Guidelines and partner to keep workers and the surrounding community safe.

For institutions that manage their IBC internally, Sitero can provide committee support and coordination. This can be as little or as much support as an institution needs but can remove the need for a dedicated IBC coordinator on-site while also adding Biosafety expertise.